COVID-19 can significantly alter platelet counts, most commonly driving them down in people with severe illness. A meta-analysis of over 7,600 patients found that those with severe disease had markedly lower platelet counts than those with milder infections, and non-survivors had even lower counts than survivors.1Frontiers in Immunology. Does SARS-CoV-2 infect platelets? But the relationship between SARS-CoV-2 and platelets turns out to be far more complex than a simple drop in numbers. The virus can infect the very cells that produce platelets, trick the immune system into destroying them, and hyperactivate the ones that remain, all at once.
Low Platelet Counts Show Up Often in Severe Cases
Thrombocytopenia, the medical term for a low platelet count, is one of the more consistent lab findings in hospitalized COVID-19 patients. In one study from an Ethiopian hospital’s COVID treatment center, roughly one in four patients had low platelet counts on admission, and the odds of having them were about four to six times higher in moderate and severe cases compared to mild ones.2PubMed Central. Baseline Thrombocytopenia and Disease Severity Among COVID-19 Patients, Tibebe Ghion Specialized Hospital COVID-19 Treatment Center, Northwest Ethiopia A study of hospitalized Egyptian patients found the same pattern: low platelet counts were substantially more common in severe and critically ill patients than in those with milder illness.3Annals of Medicine and Surgery. Association between thrombocytopenia and the severity of Covid-19 infection among hospitalized Egyptian patients
The pooled data paints a clearer picture. That large meta-analysis of 31 studies estimated a roughly threefold increase in the risk of developing severe COVID-19 among patients who arrived with low platelet counts.1Frontiers in Immunology. Does SARS-CoV-2 infect platelets? Doctors quickly learned to treat falling platelet numbers as a warning sign, and some research has explored whether related measures like mean platelet volume can predict outcomes with even greater accuracy.4Heliyon. Can mean platelet volume be a prognosis predictor in viral infections: An example of Covid-19
The Virus Can Infect the Cells That Make Platelets
One of the more unsettling discoveries about SARS-CoV-2 is that it doesn’t just cause indirect damage to the blood system. The virus appears capable of directly infecting megakaryocytes, the large bone marrow cells responsible for producing platelets. Researchers using electron microscopy found viral particles inside bone marrow megakaryocytes of COVID-19 patients with low platelet counts, and further testing confirmed the presence of two specific SARS-CoV-2 proteins along with signs suggesting the virus was actively replicating inside these cells.5Journal of Thrombosis and Haemostasis. Detection of SARS-CoV-2 in bone marrow megakaryocytes and elevated emperipolesis in COVID-19 patients with thrombocytopenia
This wasn’t an isolated finding. Another team identified circulating megakaryocytes in the blood of COVID patients that carried the SARS-CoV-2 spike protein, splitting them into virus-positive and virus-negative populations.6PubMed Central. Circulating SARS-CoV-2 + megakaryocytes are associated with severe viral infection in COVID-19 Meanwhile, autopsy studies of patients who died from COVID-19 found infected megakaryocytes in both the bone marrow and the lungs. In one study, platelets from 19 out of 20 non-survivors contained SARS-CoV-2, a finding that correlated tightly with fatal outcomes. Those infected platelets likely originated from infected megakaryocytes in both locations.7PubMed Central. Infection of lung megakaryocytes and platelets by SARS-CoV-2 anticipate fatal COVID-19
If the virus is hijacking the factories that make platelets, it makes sense that platelet production could slow down or produce defective platelets. But infection of megakaryocytes is only one piece of the puzzle.
The Bone Marrow Gets Hit From Multiple Directions
Beyond direct viral invasion, the inflammatory storm that accompanies severe COVID-19 hammers the bone marrow indirectly. High levels of inflammatory signaling molecules, particularly interleukin-6, have been found to disrupt the normal formation of megakaryocytes.8Experimental Hematology. Interaction of the inflammatory response and megakaryocytes in COVID-19 infection Other inflammatory proteins like interferons and TNF-alpha can suppress the production and maturation of blood-forming stem cells more broadly, which helps explain why some COVID-19 patients develop low counts across multiple blood cell types, not just platelets.9Current Research in Translational Medicine. Bone marrow alterations in COVID-19 infection: The root of hematological problems
The result is a two-pronged attack on platelet production: the virus infects megakaryocytes directly, and the body’s own inflammatory response makes it harder for the bone marrow to compensate.
The Immune System Sometimes Destroys Its Own Platelets
Some patients develop an autoimmune reaction in which the body mistakenly targets its own platelets for destruction. This condition, called immune thrombocytopenic purpura (ITP), has been reported in COVID-19 patients and can cause platelet counts to plummet rapidly. One proposed mechanism involves molecular mimicry: viral proteins resemble proteins on the surface of platelets closely enough that antibodies made to fight the virus also attack the platelets.10PubMed Central. COVID-19 induced immune thrombocytopenic purpura: case report
A systematic review of SARS-CoV-2-related ITP catalogued several additional immune mechanisms at play, including broader immune dysregulation and a process called epitope spreading, where the immune attack that starts against one target gradually widens to hit others.11PubMed Central. Immune Thrombocytopenia Secondary to COVID-19: a Systematic Review These autoimmune effects can appear during the acute infection or even weeks later, after the virus itself has been cleared.
Platelets Get Used Up in Widespread Clotting
COVID-19 earned a reputation early in the pandemic for causing unusual blood clots, and platelets are central to that story. In severe infections, platelets become hyperactivated, releasing substances that fuel a cycle of inflammation and clotting. Activated platelets interact with white blood cells to promote the formation of neutrophil extracellular traps (NETs), web-like structures that snare pathogens but also damage blood vessel walls and trigger more clotting.12Nature Reviews Immunology. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19 As platelets are consumed in this cascade of tiny clots throughout the body, the count in circulating blood drops.
This process, often called immunothrombosis, is a central feature of COVID-19 coagulopathy. Researchers have drawn a distinction between the clotting disorder seen in COVID-19 and more familiar clotting conditions like disseminated intravascular coagulation (DIC). In COVID-19, many of the standard clotting lab tests can look surprisingly normal or even shortened, fibrinogen levels don’t typically drop, and the abnormality often starts locally in the lungs before spreading elsewhere.13PubMed Central. Coagulopathy during COVID-19 infection: a brief review14Journal of Intensive Medicine. Understanding COVID-19-associated coagulopathy: From PIC to SIC or DIC This distinctive pattern meant that a low platelet count alone didn’t tell the whole story; clinicians had to interpret it alongside other clotting markers to understand what was happening.
What Autopsies Showed
Autopsy studies provided some of the most striking visual evidence of how COVID-19 disrupts platelets. In a case series of seven patients, every autopsy revealed platelet-rich blood clots lodged in the tiny vessels of the lungs, liver, kidneys, and heart, regardless of whether the patient had received blood-thinning medications. The lungs of COVID-19 patients contained roughly three times the normal number of megakaryocytes compared to patients who had died of other causes of respiratory failure, and the heart showed a similar pattern.15eClinicalMedicine. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series Bone marrow megakaryocytes also appeared to be in overdrive, showing structural signs of active platelet production, as if the body was trying desperately to replace what was being lost.16EClinicalMedicine. Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: A case series
The presence of megakaryocytes in organs where they don’t normally concentrate, particularly the lungs and heart, suggested that the body was producing platelets outside the bone marrow in an emergency effort to keep up with demand. This phenomenon of displaced platelet production added another layer to the understanding of how COVID-19 disrupts normal blood cell biology.
Platelet Counts Can Also Spike
While low platelet counts get most of the attention, COVID-19 can push counts in the opposite direction. In one documented case, a patient was admitted with normal platelet numbers that then climbed above 1,000 × 10⁹/L, a level classified as extreme thrombocytosis, as the clinical condition worsened.17PubMed Central. COVID-19 with Extreme Thrombocytosis: A Case Report and Its Possible Mechanisms The proposed explanation involves the same inflammatory signals that suppress the bone marrow in some patients: in other patients, those signals overstimulate megakaryocyte production, flooding the bloodstream with platelets. This rebound effect can also occur during recovery from an initial drop. Either way, extremely high platelet counts during COVID-19 are considered a red flag for worsening disease.
The Platelets Themselves Are Reprogrammed
Even when platelet counts stay within a normal range, the platelets in COVID-19 patients are not behaving normally. Gene expression studies have revealed sweeping changes in the molecular profile of circulating platelets during infection. One study found over 3,000 genes with altered activity in the platelets of COVID patients compared to healthy donors, with changes concentrated in pathways related to protein processing, immune signaling, and energy production.18PubMed Central. Platelet gene expression and function in patients with COVID-19 A separate analysis confirmed that SARS-CoV-2 altered both the coding and non-coding portions of the platelet’s genetic instructions, promoting clot formation and disrupting the cells’ energy metabolism.19PubMed Central. Transcriptional landscape of circulating platelets from patients with COVID-19 reveals key subnetworks and regulators underlying SARS-CoV-2 infection
This matters because it means a standard blood count showing a “normal” number of platelets can mask serious underlying dysfunction. The platelets may be present in adequate numbers but behaving in a pro-clotting, pro-inflammatory way that increases the risk of complications. A simple count doesn’t capture that.
Platelet Problems in Long COVID
Platelet abnormalities don’t always resolve when the acute infection ends. Research into long COVID has identified persistent signs of vascular damage and clotting abnormalities, including altered platelet counts, in people experiencing ongoing symptoms weeks and months after their initial illness.20Journal of Thrombosis and Haemostasis. Thromboinflammation in long COVID—the elusive key to postinfection sequelae? A study of 80 long COVID patients found significant fibrin-based microclots and platelet abnormalities in every single case examined, and these pathologies tracked with the persistence of long COVID symptoms.21PubMed Central. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with Long COVID/Post-Acute Sequelae of COVID-19 (PASC)
Whether these persistent platelet abnormalities are a cause of long COVID symptoms or merely a marker of ongoing vascular injury is still being worked out. But for people wondering why they still feel unwell months after testing negative, microclots and lingering platelet dysfunction have become one of the more actively investigated hypotheses.
Children and MIS-C
Children generally experience milder acute COVID-19, but a small number develop multisystem inflammatory syndrome in children (MIS-C), a delayed hyperinflammatory response that typically appears weeks after the initial infection. A meta-analysis of inflammatory markers in MIS-C found that these children had lower platelet counts compared to children hospitalized with severe COVID-19 itself.22PubMed Central. The inflammatory markers of multisystem inflammatory syndrome in children (MIS-C) and adolescents associated with COVID-19: A meta-analysis This is somewhat counterintuitive, since MIS-C is an inflammatory syndrome rather than an acute viral infection, but the combination of low platelets with high inflammatory markers became one of the diagnostic clues clinicians used to identify MIS-C and distinguish it from other childhood illnesses.
Vaccine-Induced Thrombocytopenia Was Real but Rare
Early in the vaccination rollout, reports surfaced of a rare but serious condition called vaccine-induced immune thrombotic thrombocytopenia (VITT), primarily linked to adenovirus-based COVID vaccines. VITT involves an unusual combination of blood clots and low platelet counts, driven by antibodies that bind to platelet factor 4 (PF4) complexes and trigger massive platelet activation.23Frontiers in Immunology. Pathogenic Mechanisms of Vaccine-Induced Immune Thrombotic Thrombocytopenia in People Receiving Anti-COVID-19 Adenoviral-Based Vaccines: A Proposal Laboratory work showed that these anti-PF4 antibodies co-activated both the complement system and platelets, and that treatment with intravenous immunoglobulin could suppress the runaway platelet clumping.24PubMed Central. COVID-19 adenovirus vaccine triggers antibodies against PF4 complexes to activate complement and platelets
VITT was extremely rare, affecting a tiny fraction of vaccine recipients, and the condition was specifically associated with adenovirus-vector vaccines rather than mRNA vaccines. The discovery led to diagnostic guidelines and treatment protocols that significantly improved outcomes for the small number of affected individuals. Recognizing the mechanism also helped clinicians avoid heparin, a standard blood thinner that can worsen PF4-mediated clotting disorders.
Aspirin Didn’t Turn Out to Be the Answer
Given how central platelet hyperactivation is to COVID-19’s clotting complications, there was early enthusiasm for antiplatelet drugs like aspirin. The logic was straightforward: if overactive platelets are driving clots, calm the platelets down. But the evidence hasn’t supported routine aspirin use. The large RECOVERY trial randomized nearly 15,000 hospitalized COVID-19 patients and found that aspirin did not reduce 28-day mortality or the risk of needing a ventilator. It produced a small reduction in clotting events but an essentially equal increase in major bleeding.25PubMed Central. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial A meta-analysis of randomized trials confirmed no significant effect of aspirin on overt clotting events in COVID patients overall.26PubMed Central. Associations between the use of aspirin or other antiplatelet drugs and all-cause mortality among patients with COVID-19: A meta-analysis The takeaway was that COVID-19 coagulopathy, while heavily involving platelets, is not the same kind of clotting problem that aspirin was designed to address.
A Lab Test Pitfall Worth Knowing About
There’s an artifact that can make platelet counts look falsely low in COVID patients, potentially triggering unnecessary alarm or treatment. Standard blood samples are collected in tubes containing EDTA, an anticoagulant that prevents clotting. In some patients with persistent COVID-related antibodies, EDTA causes platelets to clump together in the tube, and the lab machine reads those clumps as fewer individual platelets. One case report documented this EDTA-induced pseudothrombocytopenia persisting up to nine months after the initial COVID-19 infection, coinciding with ongoing anti-SARS-CoV-2 antibody positivity. When the same patient’s blood was drawn into a tube with a different anticoagulant, the platelet count came back normal.27Laboratory Medicine. EDTA-Induced Pseudothrombocytopenia up to 9 Months after Initial COVID-19 Infection Associated with Persistent Anti-SARS-CoV-2 IgM/IgG Seropositivity
If you’ve had COVID and a blood test shows an unexpectedly low platelet count but you feel fine and have no bruising or bleeding, it’s worth asking whether the result might be a lab artifact rather than a real drop. A peripheral blood smear, where a technician looks at the blood under a microscope, can usually spot platelet clumps and settle the question.
COVID Is Not Unique in Targeting Platelets
Low platelet counts are actually a hallmark of poor prognosis across many viral infections, not just COVID-19. Viruses interact with platelets and megakaryocytes through a variety of direct and indirect routes, and the resulting platelet activation and consumption contribute to low counts in conditions ranging from dengue to influenza.28PubMed Central. Platelets in Viral Infections – Brave Soldiers or Trojan Horses What made SARS-CoV-2 somewhat distinctive was the scale and variety of its platelet effects: direct infection of megakaryocytes, autoimmune destruction, massive immunothrombotic consumption, gene-level reprogramming of platelet function, and persistent abnormalities lasting months. Few other common respiratory viruses hit all of these pathways simultaneously with the same intensity, which is part of why COVID-19’s clotting complications were so striking early in the pandemic.